Tetraphase Pharmaceuticals, Inc. Securities Litigation
On or around 07/17/2020 (Date of last review)
Filing Date: July 16, 2020
According to the Complaint, Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company that uses its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform.
This action stems from a proposed transaction announced on June 24, 2020, pursuant to which Tetraphase Pharmaceuticals, Inc. will be acquired by La Jolla Pharmaceutical Company. On June 24, 2020, Tetraphase’s Board of Directors caused the Company to enter into an agreement and plan of merger with La Jolla.
On June 29, 2020, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
Company & Securities Information
Defendant: Tetraphase Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TTPH
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Patrick Plumley, et al. v. Tetraphase Pharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 20-CV-00955
DATE FILED: 07/16/2020
CLASS PERIOD START: 06/24/2020
CLASS PERIOD END: 07/16/2020
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available